Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug could shield brain after bleeding stroke

NCT ID NCT05664191

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether levosimendan, a heart medication that widens blood vessels, can reduce dangerous artery spasms and delayed brain injury after a type of bleeding stroke called aneurysmal subarachnoid hemorrhage. Thirty adults in intensive care will receive either levosimendan or a placebo on day 1 and day 8. The study tracks complications like death, vasospasm, and delayed brain ischemia over 14 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levosimendan
What this could lead to
If it works, this could point toward a treatment to prevent brain damage after a bleeding stroke.
What could go wrong
This is a very small, early pilot study with only 30 patients, so results may not be conclusive. The drug may not reduce complications or could cause side effects like low blood pressure or fast heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Started

Oct 2023

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All adult patients (18 to 75 years old), * hospitalized in surgical intensive care at Lariboisière Hospital for subarachnoid haemorrhage of aneurysmal origin * WFNS clinical score of I to IV and a mFisher score of 3 or 4. Exclusion Criteria: * pregnant women * contraindications to levosimendan (including hypersensitivity to levosimendan, severe hypotension (mean arterial pressure less than 65 mmHg), tachycardia (heart rate greater than 120 bpm), cardiac mechanical obstructions) * severe renal failure (creatinine clearance \< 30 ml/min) * severe hepatic failure (signs of hepatic encephalopathy) or chronic liver disease * history of torsades de pointes * pre-existing severe neurovascular pathologies. * Moribund patients. * Patient not affiliated to social security * Patient participating in another interventional research * Patients under legal guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage stroke disorder subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sub-arachnoid haemorrhage

Contacts and locations

Locations

  • Hôpital Lariboisière, Service d'anesthésie Réanimation

    Paris, France, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.